AR016295A1 - Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme - Google Patents

Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme

Info

Publication number
AR016295A1
AR016295A1 ARP980103181A ARP980103181A AR016295A1 AR 016295 A1 AR016295 A1 AR 016295A1 AR P980103181 A ARP980103181 A AR P980103181A AR P980103181 A ARP980103181 A AR P980103181A AR 016295 A1 AR016295 A1 AR 016295A1
Authority
AR
Argentina
Prior art keywords
antigen
compositions
proteins
disease
lyme
Prior art date
Application number
ARP980103181A
Other languages
English (en)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of AR016295A1 publication Critical patent/AR016295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un nuevo antígeno aislado de superficie Borrelia burgdorferi caracterizado por una masa molecular relativa de 39.5 kDa. Este antígeno se expresa in vitromediante espiroquetas de la cepa B. burgdorferi. Este antígeno induce anticuerpos que matan las espiroquetas de la cepa B. burgdorferi sensu lato mediante ADCKin vitro. También son utiles las nuevas proteínas de filamento de cassette Borrelia o fragmentos de la misma tal como la proteína P39.5 para diagnosticar laenfermedad de Lyme y en composiciones para el tratamiento o profilaxis de la misma.
ARP980103181A 1997-06-30 1998-06-30 Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme AR016295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5127197P 1997-06-30 1997-06-30

Publications (1)

Publication Number Publication Date
AR016295A1 true AR016295A1 (es) 2001-07-04

Family

ID=21970280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103181A AR016295A1 (es) 1997-06-30 1998-06-30 Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme

Country Status (17)

Country Link
US (2) US6660274B2 (es)
EP (1) EP1012181B1 (es)
JP (1) JP2002511760A (es)
KR (1) KR20010020567A (es)
CN (1) CN1261896A (es)
AR (1) AR016295A1 (es)
AT (1) ATE337335T1 (es)
AU (1) AU8177298A (es)
CA (1) CA2294701C (es)
CO (1) CO4790101A1 (es)
DE (1) DE69835682T2 (es)
DK (1) DK1012181T3 (es)
ES (1) ES2270523T3 (es)
NO (1) NO996514L (es)
PL (1) PL337667A1 (es)
WO (1) WO1999000413A1 (es)
ZA (1) ZA985704B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589109B1 (en) * 1996-02-21 2017-04-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic borrelia
US6660274B2 (en) * 1997-06-30 2003-12-09 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2004058181A2 (en) 2002-12-20 2004-07-15 Board Of Regents, The University Of Texas System Vmp-like sequences of pathogenic borrelia species and strains
WO2007133623A2 (en) * 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
UA99719C2 (ru) 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
ES2337113B1 (es) * 2007-04-17 2011-01-24 Centre De Recerca En Sanitat Animal (Cresa) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante.
EP2191266A4 (en) * 2007-09-07 2011-08-03 Univ California BORRELIA DIAGNOSTIC AND SCREENING METHOD
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
EP2501719B1 (en) 2009-11-17 2015-11-04 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
CN103229055A (zh) 2010-09-27 2013-07-31 康奈尔大学 莱姆病的诊断方法
WO2013067448A2 (en) 2011-11-03 2013-05-10 Vca Antech Inc. Compositions and methods to detect various infectious organisms
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
US9670537B2 (en) 2014-06-06 2017-06-06 Titan Collaborative Kithe, Llc Borrelia Provocation Procedure kit
WO2016049148A1 (en) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions and methods for te diagnosis of lyme disease
CN108351355A (zh) 2015-08-27 2018-07-31 奎多公司 具有两个流体流动路径用于检测和区分两个或多个分析物的免疫分析测试设备
CN108139401B (zh) * 2015-09-25 2022-02-18 凯杰科技有限公司 诊断莱姆病并用于预测治疗后莱姆病螺旋体消除的组合物和方法
CN106397589A (zh) * 2016-10-31 2017-02-15 杭州贝英福生物科技有限公司 一种狭义伯氏疏螺旋体多克隆抗体及应用
CN106432487A (zh) * 2016-10-31 2017-02-22 杭州贝英福生物科技有限公司 一种伽氏疏螺旋体多克隆抗体及应用
CA3053110A1 (en) 2017-02-10 2018-08-16 Quidel Corporation Lateral flow assay with substrate having channels for controlled fluid flow
CN109596824A (zh) * 2019-01-04 2019-04-09 杭州奥泰生物技术股份有限公司 一种快速诊断莱姆病的检测试纸及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485551A (en) 1892-11-01 And william
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
EP0339695A3 (en) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
JPH05501113A (ja) 1990-03-05 1993-03-04 アメリカ合衆国 ボレリア　ブルグドルフェリの抗原性タンパク質
CA2084413A1 (en) 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
EP1589109B1 (en) 1996-02-21 2017-04-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic borrelia
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6660274B2 (en) * 1997-06-30 2003-12-09 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6475492B1 (en) * 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease

Also Published As

Publication number Publication date
AU8177298A (en) 1999-01-19
ZA985704B (en) 1999-01-13
ATE337335T1 (de) 2006-09-15
ES2270523T3 (es) 2007-04-01
DE69835682T2 (de) 2007-08-23
NO996514D0 (no) 1999-12-28
NO996514L (no) 2000-02-14
US20040067517A1 (en) 2004-04-08
KR20010020567A (ko) 2001-03-15
DE69835682D1 (de) 2006-10-05
JP2002511760A (ja) 2002-04-16
US6660274B2 (en) 2003-12-09
CA2294701A1 (en) 1999-01-07
CN1261896A (zh) 2000-08-02
CA2294701C (en) 2009-09-08
PL337667A1 (en) 2000-08-28
CO4790101A1 (es) 1999-05-31
EP1012181A1 (en) 2000-06-28
EP1012181B1 (en) 2006-08-23
US20030059894A1 (en) 2003-03-27
DK1012181T3 (da) 2007-01-02
WO1999000413A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE69940404D1 (de) Multikomponenten Impfstoffe gegen Staphylococcus aureus
EP1427744A4 (en) SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
DE69940775D1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
RU95105518A (ru) Применение мутантов вируса герпеса, вакцина
ATE132197T1 (de) Monoklonale antikörper
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
AR004360A1 (es) Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
PT640098E (pt) Gene de coronavirus canino e suas utilizacoesc
DK0938329T3 (da) Immunogen TLP sammensætning
Yoo et al. Experimental salivary pellicles formed on the surface of self‐curing resin
EP2166096A3 (en) Moraxella (Branhamella) catarrhalis antigens
ATE321863T1 (de) Diagnostischer test für von pferdearthritisvirus verursachte krankheiten

Legal Events

Date Code Title Description
FB Suspension of granting procedure